New Zealand markets closed

Clovis Oncology, Inc. (CLVS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.2002-0.0221 (-9.94%)
At close: 04:00PM EST
0.2060 +0.01 (+2.90%)
After hours: 07:58PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 49.84M
Enterprise value 672.14M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.30
Price/book (mrq)N/A
Enterprise value/revenue 5.05
Enterprise value/EBITDA -3.21

Trading information

Stock price history

Beta (5Y monthly) 0.22
52-week change 3-92.59%
S&P500 52-week change 3-15.73%
52-week high 33.3200
52-week low 30.2000
50-day moving average 30.7442
200-day moving average 31.3444

Share statistics

Avg vol (3-month) 34.18M
Avg vol (10-day) 32.88M
Shares outstanding 5144.96M
Implied shares outstanding 6N/A
Float 8142.86M
% held by insiders 11.44%
% held by institutions 125.90%
Shares short (14 Nov 2022) 428.02M
Short ratio (14 Nov 2022) 44.75
Short % of float (14 Nov 2022) 419.70%
Short % of shares outstanding (14 Nov 2022) 419.33%
Shares short (prior month 13 Oct 2022) 431.49M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin -189.37%
Operating margin (ttm)-155.16%

Management effectiveness

Return on assets (ttm)-30.18%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)133.02M
Revenue per share (ttm)0.96
Quarterly revenue growth (yoy)-19.10%
Gross profit (ttm)115.3M
EBITDA -198.68M
Net income avi to common (ttm)-251.91M
Diluted EPS (ttm)-2.0840
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)58.32M
Total cash per share (mrq)0.4
Total debt (mrq)680.62M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.14
Book value per share (mrq)-2.89

Cash flow statement

Operating cash flow (ttm)-175.58M
Levered free cash flow (ttm)-128.19M